Lifeline Drugs & Pharma (Delisted) financials and balance sheet

BSE: 506113Retailing

Last traded ₹134.40 on 27 Aug 2015

Delisted on 23 Nov 2023.

10 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Lifeline Drugs & Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹62 Cr, year to Mar 2010

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2018

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue4.1
  2. Materials and goods−5.1
  3. Employee costs0.0
  4. Other expenses0.0
  5. Operating profit−1.0
  6. Depreciation0.0
  7. Other income+1.0
  8. One-off items0.0
  9. Finance costs0.0
  10. Profit before tax0.0
  11. Tax0.0
  12. Net profit0.0

What the company owns

  • Plant, investments and other assets₹13,63,526 Cr
  • Inventory₹9,14,326 Cr
  • Cash and bank₹27,482 Cr
  • Receivables₹4,667 Cr

What pays for it: net worth and liabilities

  • Net worth₹21,59,497 Cr
  • Owed to suppliers₹1,50,350 Cr
  • Other liabilities₹154 Cr

Lifeline Drugs & Pharma business segments, year to Mar 2018

A reportable segment is a line of business the company must report on its own. Standalone, ₹ crore, as the company reports them. A segment at a loss has no share of profit.Lifeline Drugs & Pharma segment results by quarter

Revenue by segment

₹5.14 CrTotal
  • Finance and Investment activities₹4.86 Cr94.5% of total
  • Textile Activities₹0.26 Cr5.0% of total
  • Steel Activities₹0.02 Cr0.5% of total

Profit by segment

  • Finance and Investment activities₹0.05 Cr69.4% of total
  • Steel Activities₹0.02 Cr30.6% of total

Segment results by year

Standalone, ₹ crore, years to March.

  • Finance and Investment activities

    Revenue, ₹ crore
    Profit, ₹ crore
  • Textile Activities

    Revenue, ₹ crore
    Profit, ₹ crore
  • Steel Activities

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreMar 2018
Revenue of all businesses5.14
Company revenue, as in its results4.15
Revenue4.86
Profit0.05
Margin1.1%
Revenue0.26
Revenue0.02
0.00
Profit is before tax and finance costs, the way companies report their segments.

Profit and loss

Standalone, ₹ crore, years to March. No results on record for the years to Mar 2011 and Mar 2016.Lifeline Drugs & Pharma quarterly results

₹ croreMar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Filed 30 Nov
Revenue from operations62.162.2–––40.142.7–3.54.1
–––––––––5.1
Materials and goods bought61.361.7–––39.643.1–4.55.1
Employee costs–––––––––0.0
Other expenses–––––––––0.0
Operating profit before depreciation–––––––––−1.0
Operating margin–––––––––−24.0%
Materials, % of revenue–––––––––122.7%
Employee costs, % of revenue–––––––––0.6%
Other expenses, % of revenue–––––––––0.6%
Depreciation and amortisation–––––0.00.0–0.00.0
Operating profit after depreciation–––––––––−1.0
Other income–––0.10.30.81.6–1.11.0
Finance costs0.00.0–––––––0.0
One-off items–––––––––0.0
Profit before tax0.50.4–0.10.21.00.9–0.00.0
0.20.1––0.10.30.3–0.00.0
Net profit0.40.3–0.10.10.70.6–0.00.0
Net margin0.6%0.4%–––1.6%1.5%–0.1%0.0%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2009 and Mar 2010: the statement does not state its depreciation, which operating profit is worked out from, so operating profit is not given. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2012 and Mar 2013: the statement does not state its revenue, finance costs or depreciation, which operating profit is worked out from, so operating profit is not given. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2014, Mar 2015 and Mar 2017: the statement does not state its finance costs, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2018Filed 30 Nov
21,59,497
Share capital3,62,400
Reserves17,97,097
Borrowings0
1,50,504
Liabilities due after a year0
Total assets23,10,001
9,298
23,00,703
Net debt−27,482
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2009, Mar 2010, Mar 2012, Mar 2013, Mar 2014, Mar 2015 and Mar 2017, so its lines and the ratios worked from it are blank there.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Filed 30 Nov
–––₹0.17–₹0.00₹0.00
As stated that year₹2.12₹0.46–₹0.17–₹0.00₹0.00
–––₹0.17–₹0.00₹0.00
Market cap at the year end (₹ crore)111–714–––
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Standalone, years to March.

RatioMar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Filed 30 Nov
Revenue growth23.4%0.3%––––6.5%––19.1%
Net profit growth25.7%−24.4%––176.5%364.5%−4.7%––−84.0%
Earnings per share growth–––––––––0.0%
Return on equity–––––––––0.0%
Return on capital employed–––––––––0.0%
Debt to equity–––––––––0.00
Receivable days–––––––––4,10,856
Inventory days–––––––––6,55,78,510
Payable days–––––––––1,07,83,618
Cash conversion cycle, days–––––––––5,52,05,747
Working capital days–––––––––18,68,58,942
Asset turnover–––––––––0.00
Assets per rupee of net worth–––––––––1.07
Sales per rupee of plant–––––––––0.01
Plant being built, % of plant in use–––––––––0.0%
Interest cover is left blank for the year to Mar 2018: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2009, Mar 2010, Mar 2012, Mar 2013, Mar 2014, Mar 2015 and Mar 2017, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2018.

Return on assets, latest year
0.0%
Measure10 years5 years3 years
Revenue growth, yearly rate−22.1%–−54.0%
Profit growth, yearly rate−44.3%−64.5%−89.1%
Net margin, average–0.8%0.1%

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Altman Z-scorePublished threshold 1.1–––––––––23.71
Effective tax ratePublished threshold 17.16 per cent33.2133.50––30.8832.9231.13–−25.0011.11
A threshold marked as ours has no published figure; it is the line we read the check against.